-
BAPTA-AM Workflows for Calcium Signaling Studies
2026-09-26
Use BAPTA-AM to test whether intracellular Ca²⁺ changes drive a phenotype—not merely accompany it. This practical guide adapts organophosphorus neuropathy findings into controlled cell-assay workflows, with loading, readout, and troubleshooting advice.
-
DDRGK1–UFMylation restrains STAT3 in osteoarthritis
2026-09-26
A 2026 study identifies DDRGK1-mediated UFMylation as a brake on STAT3 phosphorylation and nuclear signaling in osteoarthritis. Human cartilage observations, mouse models, and molecular assays link loss of this regulatory axis to cartilage damage and suggest STAT3 inhibition as a potential means of modifying disease phenotypes.
-
Tamsulosin Workflows for Ureteral Stone Research
2026-09-25
Translate Tamsulosin’s α₁A-receptor pharmacology into practical smooth-muscle, receptor-signaling, and ureteral transport experiments. A large meta-analysis supports clinically relevant endpoint selection, while the workflow below separates that evidence from assay conditions that researchers should optimize locally.
-
Hybrid Core-Shell Particles for Systemic mRNA Delivery
2026-09-25
Andretto and colleagues tested whether a hyaluronic acid (HA) coating could alter liposome–mRNA complexes while retaining their mRNA association and transfection performance. Their results distinguish nanoparticle biodistribution from the location of translated protein: particles accumulated in the hepatic reticuloendothelial system, whereas expression was detected mainly in the spleen, particularly in macrophages.
-
Rocilinostat (ACY-1215) in Myeloma Assays
2026-09-24
Use Rocilinostat (ACY-1215) to test HDAC6 target engagement, myeloma-cell responses, and combinations with proteasome inhibitors in controlled preclinical assays. A practical workflow pairs α-tubulin acetylation with viability and apoptosis readouts while keeping the distinct SMPD4 brain-development findings in their proper biological context.
-
Ro 3306: A Selective CDK1 Inhibitor
2026-09-24
Ro 3306 is an ATP-competitive CDK1 inhibitor used to block mitotic entry and support cell cycle G2/M phase arrest. Its reported kinase selectivity and research applications make it useful for cancer cell synchronization and DNA repair mechanism studies, but experimental outcomes depend on cell type and treatment conditions.
-
Beyond Antibiotics: Translational Lessons from YZ462
2026-09-23
YZ462 illustrates how membrane disruption, permeability changes, oxidative stress, and biofilm activity can create a differentiated antibacterial development strategy against MRSA. This article translates those findings into a disciplined research framework and shows how Recombinant Human IL-12 can be evaluated as a hypothesis-generating host-response variable without overstating the current evidence.
-
Laminin (925-933): An Assay-Design Guide
2026-09-23
Laminin (925-933) is a defined Laminin B1 chain peptide for dissecting receptor-dependent adhesion and chemotaxis. This guide connects its biochemical precision with model-selection principles from recent tau research to improve cell migration and extracellular matrix assay design.
-
Dual-Action Inhibition of p38α Dephosphorylation
2026-09-22
The reference study shows that some kinase inhibitors do more than block the p38α active site: they also reshape its activation loop to accelerate dephosphorylation by WIP1. Structural and biochemical evidence establishes a conformational mechanism that could improve the potency and specificity of future p38 MAPK-directed strategies.
-
Psora 4: A Kv1.3 Blocker for T-Cell Research
2026-09-21
Psora 4 combines strong Kv1.3 preference with a practical workflow for studying effector-memory T-cell signaling, proliferation, and cytokine responses. Its intracellular mechanism also makes channel-complex composition and inhibition kinetics important experimental variables.
-
Cefodizime Workflows for Antimicrobial Research
2026-09-21
Build reproducible Cefodizime susceptibility, time-kill, resistance, and host-response assays with practical controls for difficult Gram-negative and Gram-positive panels. The workflow separates product-specific potency data from comparative fluoroquinolone evidence, helping researchers avoid overinterpreting MIC values across methods.
-
HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody
2026-09-20
This red-fluorescent goat anti-rabbit IgG secondary antibody supports distinct workflows for ICC/IF, tissue imaging, flow cytometry, and ELISA. Its 590 nm excitation and 617 nm emission make it a practical choice for mapping biomimetic nanocarrier uptake and treatment-response biology across complementary assay formats.
-
PEG 400, Quercetin, and BCRP Efflux
2026-09-19
The reference study combines pharmacokinetics, spatial mass spectrometry imaging, transporter assays, and an inflammation model to explain how PEG 400 increases quercetin exposure and activity. Its main contribution is showing that solubility, UGT1A9-mediated metabolism, and BCRP/MRP2 efflux can act together, while also defining the limits of translating excipient effects across models.
-
TNF-α and Active Cell-Death Signaling
2026-09-19
A translational framework for using recombinant murine TNF-alpha to distinguish active apoptotic signaling from passive consequences of transcriptional stress, informed by recent RNA Pol II findings.
-
Oleanolic Acid Liposome Workflows for iNOS Studies
2026-09-18
Use Oleanolic acid as a defined lipophilic payload for connecting inducible nitric oxide synthase induction with dual-loaded liposome development. A validated nanoparticle exclusion HPLC workflow can improve separation of free and encapsulated compounds while preserving a practical path to antiviral and immune response modulation assays.